In addition, mice treated with peg-IFNG had significantly improved survival compared to control groups (median survival 79 days compared to 63 days and 67 days, p<0.05 by Log-Rank test). Together, these findings suggest that long-acting IFNG analogues may effectively enhance GvL in AML patients after HCT.
6 months ago
Preclinical
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • CIITA (Class II Major Histocompatibility Complex Transactivator) • GLI2 (GLI Family Zinc Finger 2)
P1, N=21, Completed, National Institute of Neurological Disorders and Stroke (NINDS) | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jun 2023
P1, N=20, Active, not recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Trial primary completion date: Jan 2024 --> Apr 2023
8 months ago
Trial primary completion date • Checkpoint inhibition • Checkpoint block
Table: 1121P Conclusions Our results suggest that the IFNg-signature could become a biomarker for treatment decisions in LDH low patients directing towards anti-PD1 monotherapy (in IFNg high patients) versus combination therapy, with either anti-LAG3 or anti-CTLA-4 in IFNg low patients. However, confirmation in larger cohorts and in other combination therapies is needed.
Consequently, the detection of ACAA could be important in the diagnosis of patients, particularly in the case of late-onset diseases, in order to decide appropriate treatments. This review presents an overview of current understanding of ACAA-associated secondary immunodeficiencies.
Treatment with PEG-muIFNg beginning 10 days after allo-HSCT can re-sensitize the alloTr AML1 tumors to allogeneic T cell-mediated killing and provide a significant survival advantage. Ongoing studies are also examining the candidate IFNg signaling pathway genes dysregulated in our model to determine if they are upregulated after PEG-muIFNg treatment. Furthermore, future studies will explore if extending PEG-muIFNgtreatment at the 3.8 ug concentration beyond 2 weeks can enhance GVL activity while limiting lethal GVHD.
Our study identified key genes closely related to ferroptosis in LC, which still need more studies to explore the mechanisms involved and may become effective clinical diagnostic and prognostic biomarkers.
Inhibition of IFNG pathway by the JAK1/2 inhibitor ruxolitinib or knocking out Stat1 gene abrogated the IFNG-induced melanogenesis...Moreover, cycloheximide chase assay showed that degradation of TYR was decreased in IFNG-treated cells. These results suggest that the IFNG-STAT1 pathway regulates melanogenesis via regulation of the post-translational processing and protein stability of TYR.
almost 2 years ago
Journal
|
IFNG (Interferon, gamma) • TYRP1 (Tyrosinase Related Protein 1) • DCT (Dopachrome Tautomerase) • MITF (Melanocyte Inducing Transcription Factor)
IFN-g release by AML cells induces an immune-regulatory program in MSCs and remodels BM immunological landscape toward Treg induction, contributing to an immunotolerant microenvironment.
P1, N=20, Active, not recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Completed --> Active, not recruiting | Trial completion date: Jan 2022 --> Dec 2024 | Trial primary completion date: Jan 2022 --> Jan 2024
2 years ago
Enrollment closed • Trial completion date • Trial primary completion date • Checkpoint inhibition
BCMA-CAR-T cells manufatured under GMP conditions possessed the ability for robust and specific killing of target tumor cells with a higher release of cytokines. Even after 14 or 90 days of cryopreservation, their cytotoxic functions were maintained at the same level. This give clinicians enough time to schedule the timepoint of BCMA CAR-T cell application to the patient.
2 years ago
CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
P1, N=18, Completed, National Institute of Neurological Disorders and Stroke (NINDS) | Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> Jan 2022
over 2 years ago
Trial completion • Trial completion date • Checkpoint inhibition
P1, N=18, Active, not recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Trial primary completion date: Jun 2021 --> Jan 2022
almost 3 years ago
Clinical • Trial primary completion date • Checkpoint inhibition
P1, N=18, Active, not recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Trial completion date: Jan 2022 --> Jun 2022 | Trial primary completion date: Jan 2022 --> Jun 2021
almost 3 years ago
Clinical • Trial completion date • Trial primary completion date • Checkpoint inhibition
P1, N=18, Active, not recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Jan 2022 | Trial primary completion date: Jun 2021 --> Jan 2022
3 years ago
Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Checkpoint inhibition